ArticleHepatology international2026
hnRNPA3 promotes the proliferation of hepatocellular carcinoma cells by stabilizing GLI2 proteins and activating Hedgehog pathway.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) ranks among the primary causes of cancer-related mortality, underscoring the urgent need for novel therapeutic strategies. The Hedgehog (Hh) signaling pathway, particularly the stabilization of GLI2, plays a pivotal role in cancer progression. This study aims to elucidate the functional role of heterogeneous nuclear ribonucleoprotein A3 (hnRNPA3) in HCC and its mechanistic association with GLI2 stabilization and Hh pathway activation.
methodshnRNPA3 expression levels were systematically evaluated in HCC tissues using Western blot analysis, immunohistochemistry (IHC), and survival analysis. Functional characterization was performed through in vitro assays, including CCK8 proliferation assays, colony formation assays, and xenograft models in vivo. Mechanistic investigations employed coimmunoprecipitation (Co-IP), mass spectrometry (LC-MS/MS), ubiquitination assays, and dual-luciferase reporter systems.
resultsElevated hnRNPA3 expression was consistently observed in HCC tissues and significantly correlated with poor prognosis. Overexpression of hnRNPA3 promoted HCC cell proliferation in vitro and tumor growth in vivo, whereas its knockdown exerted suppressive effects. Mechanistically, hnRNPA3 directly interacted with GLI2, inhibiting FBXW11-mediated ubiquitination and subsequent proteasomal degradation, thereby stabilizing GLI2 and activating Hh signaling pathways. Pharmacological inhibition of GLI1/2 via GANT61 effectively reversed hnRNPA3-induced proliferation.
conclusionshnRNPA3 stabilizes GLI2 by disrupting its interaction with FBXW11, thereby enhancing Hh pathway activity and contributing to HCC progression. These findings position hnRNPA3 as a potential prognostic biomarker and therapeutic target for HCC, warranting further investigation.
Indexed as
Identifiers
41191267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.